Major drugmaker loses $27 billion in market value after failed trial
From the article
Two companies announced on Thursday that the heart disease drug they had been developing failed its Phase III trial.
Continue reading on MarketWatchYou might also wanna read
AstraZeneca loses £20bn in value after major heart drug trial setback
Londonlovesbusiness·4h ago
AstraZeneca sees stock market value slump by more than £20bn after drug setback
The Independent·5h ago
AstraZeneca sees stock market value slump by more than £20bn after drug setback
ireland-live.ie·5h ago
STAT+: AstraZeneca, Ionis report major trial failure with heart disease drug
STAT·6h ago
Astrazeneca shares fall 9% after Wainua heart drug fails Phase 3 trial
Astrazeneca's stock dropped 9.1% after disappointing Phase 3 trial results for its heart drug Wainua. Over 140 weeks, the drug failed to sta
finans.dk·7h ago
AstraZeneca’s Wainua fails main goal in late-stage heart disease trial
thehindubusinessline.com·8h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.